Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00070928 · ClinicalTrials.gov registry record · Phase 2
Valerian to Improve Sleep in Patients With Parkinson's Disease
A Phase 2 study of Parkinson's Disease and Insomnia, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT00070928 is a Phase 2 study of Parkinson's Disease and Insomnia that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 80 participants, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00070928, a Phase 2 study of Parkinson's Disease and Insomnia, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this trial is to test the short-term effectiveness of valerian, a medicinal herb, to improve sleep in patients with Parkinson's disease (PD).
Conditions Studied
Interventions
- DRUG valerian
Study Locations (1)
Georgia
- Emory University Medical School/Wesley Woods Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2000-09 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00070928
The ClinicalTrials.gov registry entry for NCT00070928 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (88% lower). The listed sponsor is National Center for Complementary and Integrative Health (NCCIH), which has 203 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which valerian is the first listed.
NCT00070928 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT00070928 about?
NCT00070928 is a clinical study titled "Valerian to Improve Sleep in Patients With Parkinson's Disease". The purpose of this trial is to test the short-term effectiveness of valerian, a medicinal herb, to improve sleep in patients with Parkinson's disease (PD).
What is the current status of trial NCT00070928?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2000-09. Estimated completion is 2006-06.
What conditions does trial NCT00070928 study?
This clinical trial studies the following conditions: Parkinson's Disease, Insomnia.
What interventions are being tested in trial NCT00070928?
The interventions under investigation include: valerian (DRUG).
Who is sponsoring clinical trial NCT00070928?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00070928 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ketamine for Veterans With Parkinson's Disease
RECRUITING · Phase 2
-
Imaging Depression in Parkinson's Disease
RECRUITING · Phase 2
-
Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease
RECRUITING · Phase 2
-
Tenapanor in Synucleinopathy-Related Constipation
RECRUITING · Phase 2
-
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.